Transcriptional regulation of hTREX84 in human cancer cells

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Guo, Shanchun ^a,b   Liu, Mingli ^b   Godwin, Andrew K ^a,c  

^a FOX CHASE CANCER CENTER   (United States)

^b MOREHOUSE SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RELA;

ARTICLE; BINDING SITE; BREAST CANCER; CANCER CELL; CARCINOGENESIS; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; EPITHELIUM CELL; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE EXPRESSION REGULATION; HTREX84 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; M PHASE CELL CYCLE CHECKPOINT; MOLECULAR MECHANICS; NUCLEOTIDE SEQUENCE; ONCOGENE; OVARY CANCER; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN OVEREXPRESSION; SITE DIRECTED MUTAGENESIS; TRANSCRIPTION REGULATION;

AZACITIDINE; BASE SEQUENCE; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; EXONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA; SULFITES; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION, GENETIC;

EID: 84865437928     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043610     Document Type: Article

References (71)

1. Reed R, Cheng H, (2005) TREX, SR proteins and export of mRNA. Curr Opin Cell Biol 17: 269-273.
2. Fischer T, Strasser K, Racz A, Rodriguez-Navarro S, Oppizzi M, et al. (2002) The mRNA export machinery requires the novel Sac3p-Thp1p complex to dock at the nucleoplasmic entrance of the nuclear pores. EMBO J 21: 5843-5852.
3. Jimeno S, Rondon AG, Luna R, Aguilera A, (2002) The yeast THO complex and mRNA export factors link RNA metabolism with transcription and genome instability. EMBO J 21: 3526-3535.
4. Rondon AG, Jimeno S, Garcia-Rubio M, Aguilera A, (2003) Molecular evidence that the eukaryotic THO/TREX complex is required for efficient transcription elongation. J Biol Chem 278: 39037-39043.
5. Strasser K, Masuda S, Mason P, Pfannstiel J, Oppizzi M, et al. (2002) TREX is a conserved complex coupling transcription with messenger RNA export. Nature 417: 304-308.
6. Chavez S, Beilharz T, Rondon AG, Erdjument-Bromage H, Tempst P, et al. (2000) A protein complex containing Tho2, Hpr1, Mft1 and a novel protein, Thp2, connects transcription elongation with mitotic recombination in Saccharomyces cerevisiae. EMBO J 19: 5824-5834.
7. Piruat JI, Aguilera A, (1998) A novel yeast gene, THO2, is involved in RNA pol II transcription and provides new evidence for transcriptional elongation-associated recombination. EMBO J 17: 4859-4872.
8. Ho Y, Gruhler A, Heilbut A, Bader GD, Moore L, et al. (2002) Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry. Nature 415: 180-183.
9. Hurt E, Luo MJ, Rother S, Reed R, Strasser K, (2004) Cotranscriptional recruitment of the serine-arginine-rich (SR)-like proteins Gbp2 and Hrb1 to nascent mRNA via the TREX complex. Proc Natl Acad Sci U S A 101: 1858-1862.
10. Libri D, Dower K, Boulay J, Thomsen R, Rosbash M, et al. (2002) Interactions between mRNA export commitment, 3'-end quality control, and nuclear degradation. Mol Cell Biol 22: 8254-8266.
11. Guo S, Hakimi MA, Baillat D, Chen X, Farber MJ, et al. (2005) Linking transcriptional elongation and messenger RNA export to metastatic breast cancers. Cancer Res 65: 3011-3016.
12. Li Y, Wang X, Zhang X, Goodrich DW, (2005) Human hHpr1/p84/Thoc1 regulates transcriptional elongation and physically links RNA polymerase II and RNA processing factors. Mol Cell Biol 25: 4023-4033.
13. Rehwinkel J, Herold A, Gari K, Kocher T, Rode M, et al. (2004) Genome-wide analysis of mRNAs regulated by the THO complex in Drosophila melanogaster. Nat Struct Mol Biol 11: 558-566.
14. Masuda S, Das R, Cheng H, Hurt E, Dorman N, et al. (2005) Recruitment of the human TREX complex to mRNA during splicing. Genes Dev 19: 1512-1517.
15. Guo S, Godwin AK (2003) Accumulation of p84N5 death domain protein is associated with an aggressive phenotype of human breast tumors. Proc Am Assoc Cancer Res 548.
16. Durfee T, Mancini MA, Jones D, Elledge SJ, Lee WH, (1994) The amino-terminal region of the retinoblastoma gene product binds a novel nuclear matrix protein that co-localizes to centers for RNA processing. J Cell Biol 127: 609-622.
17. Chen PL, Chen CF, Chen Y, Xiao J, Sharp ZD, et al. (1998) The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. Proc Natl Acad Sci U S A 95: 5287-5292.
18. Gozuacik D, Murakami Y, Saigo K, Chami M, Mugnier C, et al. (2001) Identification of human cancer-related genes by naturally occurring Hepatitis B Virus DNA tagging. Oncogene 20: 6233-6240.
19. Beausoleil SA, Jedrychowski M, Schwartz D, Elias JE, Villen J, et al. (2004) Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci U S A 101: 12130-12135.
20. Gasparri F, Sola F, Locatelli G, Muzio M, (2004) The death domain protein p84N5, but not the short isoform p84N5s, is cell cycle-regulated and shuttles between the nucleus and the cytoplasm. FEBS Lett 574: 13-19.
21. Jackson-Grusby L, Beard C, Possemato R, Tudor M, Fambrough D, et al. (2001) Loss of genomic methylation causes p53-dependent apoptosis and epigenetic deregulation. Nat Genet 27: 31-39.
22. Yang J, Li Y, Khoury T, Alrawi S, Goodrich DW, et al. (2008) Relationships of hHpr1/p84/Thoc1 expression to clinicopathologic characteristics and prognosis in non-small cell lung cancer. Ann Clin Lab Sci 38: 105-112.
23. Magdinier F, Wolffe AP, (2001) Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia. Proc Natl Acad Sci U S A 98: 4990-4995.
24. Jackson K, Yu MC, Arakawa K, Fiala E, Youn B, et al. (2004) DNA hypomethylation is prevalent even in low-grade breast cancers. Cancer Biol Ther 3: 1225-1231.
25. Widschwendter M, Jones PA, (2002) DNA methylation and breast carcinogenesis. Oncogene 21: 5462-5482.
26. Dobrovic A, Simpfendorfer D, (1997) Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res 57: 3347-3350.
27. Ferguson AT, Evron E, Umbricht CB, Pandita TK, Chan TA, et al. (2000) High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci U S A 97: 6049-6054.
28. Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, et al. (1995) E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 55: 5195-5199.
29. Pakneshan P, Szyf M, Farias-Eisner R, Rabbani SA, (2004) Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis. J Biol Chem 279: 31735-31744.
30. Paredes J, Albergaria A, Oliveira JT, Jeronimo C, Milanezi F, et al. (2005) P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res 11: 5869-5877.
31. Sato N, Fukushima N, Matsubayashi H, Goggins M, (2004) Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling. Oncogene 23: 1531-1538.
32. Gupta A, Godwin AK, Vanderveer L, Lu A, Liu J, (2003) Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. Cancer Res 63: 664-673.
33. Liu H, Liu W, Wu Y, Zhou Y, Xue R, et al. (2005) Loss of epigenetic control of synuclein-gamma gene as a molecular indicator of metastasis in a wide range of human cancers. Cancer Res 65: 7635-7643.
34. Haaf T, (1995) The effects of 5-azacytidine and 5-azadeoxycytidine on chromosome structure and function: implications for methylation-associated cellular processes. Pharmacol Ther 65: 19-46.
35. Michalowsky LA, Jones PA, (1989) Gene structure and transcription in mouse cells with extensively demethylated DNA. Mol Cell Biol 9: 885-892.
36. Ghosh S, May MJ, Kopp EB, (1998) NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16: 225-260.
37. Hanahan D, Weinberg RA, (2000) The hallmarks of cancer. Cell 100: 57-70.
38. Karin M, Cao Y, Greten FR, Li ZW, (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2: 301-310.
39. Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin AS Jr, (2000) Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene 19: 1123-1131.
40. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr, (1997) Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17: 3629-3639.
41. Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, et al. (1997) Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 100: 2952-2960.
42. Biswas DK, Cruz AP, Gansberger E, Pardee AB, (2000) Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci U S A 97: 8542-8547.
43. Boyd KE, Farnham PJ, (1999) Coexamination of site-specific transcription factor binding and promoter activity in living cells. Mol Cell Biol 19: 8393-8399.
44. Orlando V, (2000) Mapping chromosomal proteins in vivo by formaldehyde-crosslinked-chromatin immunoprecipitation. Trends Biochem Sci 25: 99-104.
45. Barkett M, Gilmore TD, (1999) Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene 18: 6910-6924.
46. Chen C, Edelstein LC, Gelinas C, (2000) The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 20: 2687-2695.
47. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr, (1999) NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 19: 5785-5799.
48. Pahl HL, (1999) Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18: 6853-6866.
49. Chen CC, Manning AM (1995) Transcriptional regulation of endothelial cell adhesion molecules: a dominant role for NF-kappa B. Agents Actions Suppl 47: 135-141.
50. Garg A, Aggarwal BB, (2002) Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia 16: 1053-1068.
51. Tian B, Nowak DE, Jamaluddin M, Wang S, Brasier AR, (2005) Identification of direct genomic targets downstream of the nuclear factor-kappaB transcription factor mediating tumor necrosis factor signaling. J Biol Chem 280: 17435-17448.
52. Barnes PJ, Karin M, (1997) Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336: 1066-1071.
53. Doostzadeh-Cizeron J, Yin S, Goodrich DW, (2000) Apoptosis induced by the nuclear death domain protein p84N5 is associated with caspase-6 and NF-kappa B activation. J Biol Chem 275: 25336-25341.
54. Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, et al. (2004) NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci U S A 101: 10137-10142.
55. Eferl R, Wagner EF, (2003) AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 3: 859-868.
56. Daschner PJ, Ciolino HP, Plouzek CA, Yeh GC, (1999) Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells. Breast Cancer Res Treat 53: 229-240.
57. Johnston SR, Lu B, Scott GK, Kushner PJ, Smith IE, et al. (1999) Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin Cancer Res 5: 251-256.
58. Linardopoulos S, Malliri A, Pintzas A, Vassilaros S, Tsikkinis A, et al. (1990) Elevated expression of AP-1 activity in human breast tumors as compared to normal adjacent tissue. Anticancer Res 10: 1711-1713.
59. Stein B, Baldwin AS Jr, Ballard DW, Greene WC, Angel P, et al. (1993) Cross-coupling of the NF-kappa B p65 and Fos/Jun transcription factors produces potentiated biological function. EMBO J 12: 3879-3891.
60. Auersperg N, Maines-Bandiera SL, Dyck HG, Kruk PA, (1994) Characterization of cultured human ovarian surface epithelial cells: phenotypic plasticity and premalignant changes. Lab Invest 71: 510-518.
61. Soule HD, Maloney TM, Wolman SR, Peterson WD Jr, Brenz R, et al. (1990) Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 50: 6075-6086.
62. Tait L, Soule HD, Russo J, (1990) Ultrastructural and immunocytochemical characterization of an immortalized human breast epithelial cell line, MCF-10. Cancer Res 50: 6087-6094.
63. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, et al. (1992) High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A 89: 3070-3074.
64. Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, et al. (1983) Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res 43: 5379-5389.
65. Kwon Y, Cukierman E, Godwin AK, (2011) Differential expressions of adhesive molecules and proteases define mechanisms of ovarian tumor cell matrix penetration/invasion. Plos one 6: e18872.
66. Langdon SP, Lawrie SS, Hay FG, Hawkes MM, McDonald A, et al. (1988) Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res 48: 6166-6172.
67. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB, (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93: 9821-9826.
68. Weinmann AS, Bartley SM, Zhang T, Zhang MQ, Farnham PJ, (2001) Use of chromatin immunoprecipitation to clone novel E2F target promoters. Mol Cell Biol 21: 6820-6832.
69. Bloom HJ, Richardson WW, (1957) Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11: 359-377.
70. Elston CW, Ellis IO, (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410.
71. Zabel U, Henkel T, Silva MS, Baeuerle PA, (1993) Nuclear uptake control of NF-kappa B by MAD-3, an I kappa B protein present in the nucleus. EMBO J 12: 201-211.